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We previously described mouse hepatitis virus (MHV) variant V51 derived from a persistent infection of
murine DBT cells with an expanded host range (R. S. Baric, E. Sullivan, L. Hensley, B. Yount, and W. Chen,
J. Virol. 73:638–649, 1999). Sequencing of the V51 spike gene, the mediator of virus entry, revealed 13 amino
acid substitutions relative to the originating MHV A59 strain. Seven substitutions were located in the amino-
terminal S1 cleavage subunit, and six were located in the carboxy-terminal S2 cleavage subunit. Using targeted
RNA recombination, we constructed a panel of recombinant viruses to map the mediators of host range to the
six substitutions in S2, with a subgroup of four changes of particular interest. This subgroup maps to two
previously identified domains within S2, a putative fusion peptide and a heptad repeat, both conserved features
of class I fusion proteins. In addition to an altered host range, V51 displayed altered utilization of CEACAM1a,
the high-affinity receptor for A59. Interestingly, a recombinant with S1 from A59 and S2 from V51 was severely
debilitated in its ability to productively infect cells via CEACAM1a, while the inverse recombinant was not.
This result suggests that the S2 substitutions exert powerful effects on the fusion trigger that normally passes
from S1 to S2. These novel findings play against the existing data that suggest that MHV host range
determinants are located in the S1 subunit, which harbors the receptor binding domain, or involve coordi-
nating changes in both S1 and S2. Mounting evidence also suggests that the class I fusion mechanism may
possess some innate plasticity that regulates viral host range.
The cross-species transmission of human immunodeficiency
virus (HIV) from chimpanzees and severe acute respiratory
syndrome coronavirus (SARS-CoV) from bats and civet cats
are salient examples of zoonotic transmission into the human
population (28, 30, 36, 37). Surveys of all known human patho-
gens document this spillover, most recently noting that 58%
are zoonotic in origin, with 73% of these zoonotic pathogens
considered emerging or reemerging (59, 66). Viruses, particu-
larly RNA viruses, are well represented among emerging
pathogens (65, 67). The expansion of viruses into new hosts
remains a poorly understood process. The CoV mouse hepa-
titis virus (MHV), the prototype member and molecular model
for the genus, was utilized to study mechanisms of host range
expansion. Two models for host range expansion were estab-
lished; the first was based on a persistent infection scenario,
while the second modeled a coinfection in a mixed host cell
environment (3, 4). Variants derived from these model systems
possessed an extended host range that included normally
MHV nonpermissive hamster, monkey, feline, and human cell
lines. The utility of these model systems has been exploited
elsewhere, with a similar persistent infection system also used
by Schickli et al. to generate MHV host range variants (53).
The genus Coronavirus includes a diverse membership of
enveloped, single-stranded, positive-sense RNA viruses, his-
torically divided into three groups (I, II, and III) based on
immunological characteristics. CoVs infect a diverse repertoire
of hosts, including turkeys, cats, cattle, dogs, and humans. The
prototype group II member MHV naturally infects mice to
induce enteric or central nervous system disease, depending on
the strain. CoVs in general and MHV in particular are re-
garded as species specific, limited by availability of the appro-
priate cellular receptor to initiate infection (10, 15, 19, 21, 61,
70). The exception for MHV appears to be the neurotropic
JHM strain that has been shown in a primate model to infect
the central nervous system and also a human hepatocarcinoma
cell line (11, 32, 45). MHV binds CEACAM1 on the cell
surface to initiate infection (6, 13, 20, 46, 71). While virus
affinity for CEACAM1 and its assortment of alleles and iso-
forms varies, CEACAM1a appears to have the highest affinity
with all described MHV strains capable of initiating infection
via this receptor. CEACAMs are conserved across mammalian
genomes to include multiple representatives in the human ge-
nome (5).
The binding of MHV to its receptor is accomplished via the
envelope-anchored spike (S) glycoprotein (Fig. 1). Spike is a
class I fusion protein translated initially as a single large 180-
kDa protein that is subsequently cleaved by a cellular protease
into two noncovalently associated 90-kDa subunits, the amino-
terminal S1 subunit and carboxy-terminal S2 subunit (9, 42). A
putative receptor binding domain (RBD) has been mapped to
the first 330 amino acids of S1 and primarily determines re-
ceptor specificity (33, 62). S2 contains the transmembrane do-
main and two heptad repeat regions (HR1 and HR2) (7, 9, 16,
68). Heptad repeats are conserved features of class I fusion
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proteins that form the classic six-helix bundle believed to drive
virion-cell membrane fusion (14, 23). Several candidate fusion
peptides have been identified in S2, but none have conclusively
been demonstrated as fulfilling this role in MHV (12, 41).
Current evidence supports an infection model initiated with S1
engaging the cell surface receptor, thereby triggering a confor-
mational change in S2, leading to the fusion of the viral enve-
lope and cell membrane (26, 44, 56, 64, 74).
We previously described variant V51 with an expanded host
range phenotype to include cell lines from MHV nonpermis-
sive species (3). V51 was derived from a persistent infection of
murine DBT cells, with the infection initiated by the hepato-
tropic MHV prototype strain A59. Mutations responsible for
this expansion of host range developed between 119 and 210
days postinfection and conferred on V51 the ability to recog-
nize an assortment of human CEACAMs as receptors. Human
CEACAM usage within a given cell line was diverse and not
attributable to a single receptor allele, suggesting that addi-
tional elements were associated with V51 host range expan-
sion. The goal of this study was to isolate the genetic determi-
nants in S mediating the expanded host range phenotype of
V51.
MATERIALS AND METHODS
Cell lines and viruses. Murine DBT cells were maintained in minimum essen-
tial medium (MEM) supplemented with 6% fetal clone II (FCII) (HyClone), 5%
tryptose phosphate broth (Sigma), and 1% gentamicin-kanamycin. Human
HepG2 cells were maintained in MEM supplemented with 10% FCII, 0.1 mM
nonessential amino acids (NEAA), and 0.1 mM sodium pyruvate. Feline AKD
cells were maintained in Ham’s F12K (Kaighn’s modification) and 10% FCII.
Chinese hamster ovary K1 and pgsA-745 cells (ATCC no. CRL-2242) were
maintained in MEM, 10% FCII, and 0.1 mM NEAA. Human MCF7 cells were
maintained in Dulbecco’s modified Eagle medium supplemented with 0.1 mM
NEAA, 10% FCII, and 0.01 mg/ml insulin. Swine testicular (ST) cells stably
expressing murine CEACAM1a were produced by using CEACAM1a under the
FIG. 1. Spike protein structure map and cloning strategy. The panel of 12 chimeric S genes produced for this study is depicted, with the
approximate locations of substitutions present in V51 relative to the A59 strain indicated as vertical black bars (numerical locations are indicated
along the bottom of the figure). The 1,324-residue spike protein is typically posttranslationally cleaved between residues 717 and 718 into S1 and
S2 subunits (cleavage site indicated with black arrow). The locations of characterized functional domains are indicated with black bars. The
amino-terminal 330 residues of S1 comprise the RBD. S2 includes the putative fusion peptide PEP3 (residues 929 to 944), HR1 (residues 947 to
1048), a linker region (residues 1049 to 1214), HR2 (residues 1215 to 1262), and a transmembrane domain (TM) (residues 1264 to 1286). The four
principal PCR products generated to facilitate chimeric S gene construction are indicated flanked by the corresponding primers. Primer 1 is the
forward primer for both products in the S1 region, while primer 2 is the reverse primer for both products in the S2 region. Primer sequences are
provided, and the locations of engineered No See’m sites are marked with open arrows. Randomized nucleotides (Ns in the sequences) were
incorporated during primer synthesis to increase BsmbI restriction digest yields. Naturally occurring AlwNI (open triangle) and MluI (filled
triangle) restriction sites within S2 were used in conjunction with the engineered No See’m sites to subdivide the substitutions present in this region.
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control of a cytomegalovirus promoter in the pcDNA3 vector (kindly provided by
Kathryn Holmes). ST cells were transfected by using calcium phosphate and
stably expressing cells isolated via Geneticin selection, followed by two rounds of
sorting for CEACAM1a expression (29). ST-CEACAM1a-expressing cells were
maintained in MEM, 10% FCII, 0.1 mM NEAA, 0.1 mM sodium pyruvate, 0.005
g/ml lactoalbumin, and 1 mg/ml Geneticin. All cells were cultured at 37°C and
5% CO2.
MHV variant V51 was isolated previously (3). MHV A59 was produced via
targeted RNA recombination by using the pMH54 vector (34). Feline MHV
(fMHV) used in targeted recombination was supplied by Paul Masters, and
working stocks were produced with AKD cells.
S gene isolation and recombinant virus construction. The S gene from the
original V51 host range mutant was isolated from viral RNA by using Super-
Script II reverse transcriptase (Invitrogen), followed by PCR amplification (Ex-
pand Long Template PCR system; Roche) with the approximately 4-kb product
ligated into the TOPO-XL vector (Invitrogen). Multiple clones were selected
and sequenced to create a consensus spike gene sequence from which all recom-
binants in this study were developed. The strategy, which was used to produce
recombinant viruses with only the desired mutations, is outlined in Fig. 1. S gene
regions encoding the RBD, the S1 cleavage subunit, the S2 cleavage subunit, and
all of S, excluding the receptor binding domain (3 region), were PCR amplified
from either the V51 consensus spike or the MHV A59 donor plasmid pMH54
(kindly provided by Paul Masters) by using primers incorporating terminal No
See’m sites (BsmBI restriction sites) to allow for the seamless joining of PCR
products (34, 72). The six mutations in the S2 portion of S were subdivided by
taking advantage of unique AlwNI and MluI restriction sites present in both the
V51 and MHV A59 S genes in conjunction with the introduced BsmBI sites. The
chimeric S genes produced by combining V51 and MHV A59 pieces were then
cloned into a modified pMH54 targeting vector (pMH54mod) for the production
of virus.
pMH54mod was engineered by first removing the wild-type MHV A59 S gene
from pMH54 via unique Eco47III and EagI sites in the hemagglutinin esterase
and matrix genes, respectively. This approximately 5.5-kb restricted fragment was
replaced with a PCR product derived from pMH54 engineered to incorporate
BsmBI sites corresponding to terminal chimeric S gene BsmBI sites (Fig. 1) to
facilitate cloning. Primer HEICA59 (5-CATTCCAAGGGCAGCTCTTC-3)
was paired with RSR2BSMB (5-TGACGGACCGAGTCACGTCTCGCAATC
TAACACCGCTATCCGTC-3) to produce a PCR product spanning from the
Eco47III site to 19 nucleotides upstream of the ATG start in S. The primer
RSR2ESP (5-ACTCGGTCCGTCAGTCGTCTCAGGACACCAGGACAGT
ATTGTG-3) was paired with MREVA59 (5-AATGCCCAACGAGAAGTTC
C-3) to produce a PCR product spanning from 47 nucleotides upstream of the
S TGA stop codon to the EagI site. These two PCR products were then restricted
with RsrII (engineered into the above primers along with the BsmBI sites) to
facilitate their ligation, followed by Eco47III and EagI restriction for ligation into
the spot vacated by the original 5.5-kb restriction fragment producing
pMH54mod. All chimeric S genes begin with the ATG start of S and end 47
nucleotides upstream of the TGA S stop codon. No mutations were present in
the 3 47 nucleotides of S; hence, this sequence was preserved in the pMH54mod
vector. The common sites recombinant that incorporated mutations common to
other MHV host range model systems (positions 939 and 949) required primer-
introduced mutations using primers HSREV (5-CAGCAGCTGCCGGTGTG
CCATTTATTTTAAGCG-3) and HSFWD (5-CAGCTGCTGACCACAGTG
GGAACATAGC-3) in conjunction with the AlwNI and BsmBI sites.
The details of the fMHV-targeted RNA recombination system are well estab-
lished (34); however, the conditions used in this study are slightly altered. Briefly,
subconfluent monolayers of feline AKD cells were infected with donor virus
fMHV for 1 h at 25°C and then medium was added and the cells were incubated
at 37°C for 4 h. The infected AKD cells were then trypsinized, washed, and
resuspended in cold phosphate-buffered saline (PBS). pMH54mod plasmids
containing A59/V51 chimeric S genes were PacI digested to produce linearized
templates for transcription by using a T7-based system (mMessage mMachine;
Ambion) following the manufacturer’s instructions. Transcripts were mixed with
the cells, followed by two electroporation pulses at 50 uF and 0.3 kV (GenePulser
XCell; Bio-Rad). Electroporated cells were then overlaid onto subconfluent
layers of murine DBT cells to select for recombinants. Twenty-four to 36 h
postelectroporation, the medium was harvested and frozen. This medium was
used as a starting point for two rounds of plaque purification per recombinant.
Following the second round of purification, recombinant viral RNA was col-
lected and the S gene reverse transcription-PCR product cloned and sequenced
to verify the presence of the desired S gene mutations. Electroporations were
performed in duplicate for each construct to minimize potentially advantageous
mutations arising in the genome outside the S gene. Twice-plaque-purified and
S gene-sequence-verified viruses were then expanded for use in experiments.
Growth curve analysis. Eight-well chamber slides (Labtek) or 96-well tissue
culture plates (Corning) were seeded with the desired cell type (HepG2, MCF7,
etc.), and the cells were allowed to regain typical morphology prior to infection.
Cells were infected at a fixed multiplicity of infection (MOI) (the MOI was 5
unless explicitly stated otherwise) for 1 h at 25°C and then washed with PBS to
remove unbound virus prior to the addition of medium. Titers at various time
points were determined via plaque assay with DBT cells as described previously
(2). Briefly, 10-fold serial dilutions of virus were inoculated onto confluent DBT
cells for 1 h at 25°C and then the monolayers were overlaid with 0.8% agarose
medium. Plaques were visualized 48-h postinfection by neutral red staining and
enumerated.
Immunofluorescence staining. Chamber slides were seeded with the desired
cell type, and the cells were allowed to regain typical morphology. Cells were
infected at an MOI of 5 for 1 h at room temperature and then washed with PBS
to remove unbound virus prior to the addition of medium. At 36 h postinfection,
slides were fixed in 50:50 methanol-acetone at 20°C for at least 12 h. Fixed
slides were rehydrated for 10 min in PBS and then stained with an anti-nucleo-
capsid protein monoclonal antibody (kindly provided by Julian Liebowitz) for 2 h
at room temperature. The primary antibody was washed off and followed with
fluorescein isothiocyanate-conjugated anti-mouse secondary antibody for a half
hour at room temperature. After further washing, coverslips were mounted using
80:20 glycerol-water. Photos were taken with an Olympus IX51 microscope and
a Hamamatsu camera controlled by IP Lab software, version 3.5.
Receptor blockade assay. ST-CEACAM1a cells stably expressing CEACAM1a
[1-4] or DBT cells were seeded in chamber slides or 96-well plates as described
above. Anti-CEACAM1a monoclonal antibody CC1 (kindly provided by Kathryn
Holmes) was added to monolayers at 0.05 mg/ml in cell medium for 30 min at
37°C prior to infection (22). Cells were then infected following the growth curve
protocol described above, except that the medium added after washing unbound
virus contained CC1 or an isotype-matched control antibody (22).
RESULTS
Sequence analysis of host range mutants. It has been well
established that receptor binding and cellular entry, functions
of the S protein, determine cellular susceptibilities to MHV
and other CoV infections (10, 19, 21). Given this gatekeeper
function, the S genes from a temporal series of variants leading
to V51 (V8, V19, and V30) were individually PCR amplified,
cloned, and sequenced to develop consensus genes at each
time point (3). V8 was isolated 30 days post-initial A59 infec-
tion, V19 was isolated at 75 days post-initial A59 infection, and
V30 was isolated at 119 days post-initial A59 infection. Se-
quencing revealed the presence of 13 amino acid changes in
V51 relative to the reference A59 strain used in the targeted
RNA recombination system (Table 1). Seven substitutions
(S86T, S90P, G146D, N434K, S532A, D545G, and L652I) were
located in the S1 subunit, with three residing in the RBD. The
remaining six substitutions (M936V, P939L, F948L, S949I,
I1120T, and V1179A) were in S2. Three substitutions (S532A,
L652I, and I1120T) occurred early in variant V8 isolated at 30
TABLE 1. Substitutions in spike proteins arising during a
persistent infection
Virus
Spike protein position by residue
S1 S2
86 90 146 434 532 545 652 936 939 948 949 1120 1179
A59 S S G N S D L M P F S I V
V8 S S D N A D I M P F S T V
V19 S S G N A D I M P F I T V
V30 S S G N A D I M P F S T V
V51 T P D K A G I V L L I T A
1416 MCROY AND BARIC J. VIROL.
days postinfection and were retained throughout the remaining
180 days of infection leading to V51. Substitutions G146D and
S949I are present in early isolates V8 and V19, respectively,
and then they disappear from later-sequenced isolates, only to
reappear in V51. As previously reported, the substitutions me-
diating V51 host range expansion evolved most clearly between
119 and 210 days post-initial inoculation, corresponding to
variants V30 and V51, respectively (3). This result also repre-
sents the greatest gain in substitutions from one variant to the
next. A second V51 isolate (V51A) from the persistent infec-
tion model was also cloned and sequenced to develop a con-
sensus S gene. There are four additional substitutions in V51A
relative to A59 and V51: W259G, S537P, L1102F, and V1226I
(data not shown). V51 was selected over V51A for further
characterization for simplicity, as the altered host range phe-
notypes of both isolates were similar (3).
Two additional MHV-based systems examining host range
have previously been reported. Variants pi23, pi600, and
MHV/BHK were derived from a similar persistent infection
model of murine 17Cl1 cells, while MHV-C4 was derived from
a coinfection of MHV strains JHM and A59 in a mixed-cell
environment of both murine and hamster cells (4, 52, 53).
Comparing the S protein sequences from these variants reveals
four sites of commonality (Table 2). At position 1120, V51
shares a common isoleucine-to-threonine change with MHV/
BHK and pi600 (C4 also encodes a threonine; however, a
threonine at this position is also present in the parental JHM
strain). A second change at M936 results in leucines in MHV/
BHK and pi600, while V51 encodes a valine. At position 939,
V51 encodes a leucine in place of proline, while this codon is
deleted in C4. A substitution at site S949 is common to all
three systems. V51 encodes an isoleucine at position 949, while
C4, MHV/BHK, pi23, and pi600 share an arginine. Position
1120 is located in the linker region between HR1 and HR2.
Positions 936 and 939 are located in a region previously iden-
tified as PEP3, a putative fusion peptide (12). Position 949 is
potentially the most interesting change due to its presence in
all three systems, its location in HR1, and its close proximity to
substitutions at positions 936, 939, and 948 in V51.
Mapping determinants of host range. The critical role of S
in initiating infection has led to the identification of several of
its important regions that are responsible for receptor binding
and subsequent virion-cell membrane fusion (Fig. 1). Recom-
binant viruses containing only the desired combination of S
gene mutations were generated by using the fMHV-targeted
RNA recombination system, No See’m technology, and natu-
rally occurring restriction sites (34, 72). A panel of 12 recom-
binant viruses was produced to facilitate mapping host range
determinants (Fig. 1). Each recombinant focused on the
changes in V51 located in the recognized functional regions or
dissected the clustered changes in S2. A single recombinant,
common sites recombinant, focused on the P939 and S949
changes found in host range variants from other model sys-
tems. V51 recombinants produced plaques approximately one
quarter the size of A59 by 48 h postinfection, but plaque
margins were well defined in a manner similar to those of A59
(data not shown).
V51, but not A59, displayed robust replication in the human
hepatocarcinoma cell line HepG2 despite no previous expo-
sure during isolation (3). Thus, subsequent growth curve anal-
ysis and mapping of recombinants were performed primarily in
this cell line. Growth curve analysis was selected as the primary
assay as this represents a more stringent measure, in our opin-
ion, of the impact on host range of given changes since it relies
on the formation and recovery of a functional virion.
Given the critical role of receptor binding in determining
cellular entry and the reports implicating changes in S1 as
contributing to broad alterations in host range, the Full S, S1,
and RBD recombinants were initially produced and evaluated
to assess the contribution of substitutions in these functional
regions (17, 52, 60). By 48 h postinfection, the S1 and RBD
recombinants replicated to titers approximately 3 logs lower
(1  104 PFU/ml) than those of either the Full S recombi-
nant (8.8  106 PFU/ml) or V51 (1.3  107 PFU/ml) and
comparable to those of the A59 background (Fig. 2A). The
robustness of the Full S recombinant relative to V51 suggests
that important host range determinants are indeed located in
S; however, the involvement of other genes in determining host
range cannot be excluded. The unexpectedly low titers from
the RBD and S1 recombinants prompted us to construct the S2
and 3 region recombinants. The S2 and 3 region recombi-
nants yielded titers on par with that of V51 by 48 h postinfec-
tion (Fig. 2B). V51 replicated to 3.35  106 PFU/ml, while the
S2 recombinant peaked at 5.35  106 PFU/ml and the 3
region recombinant peaked at 1.35  107 PFU/ml. The robust
replication of both the 3 region and S2 recombinants suggests
that important determinants of host range are located exclu-
sively in S2, a phenomenon not documented previously with
CoVs. The growth curves presented in Fig. 2A and B are
representative of multiple independent experiments that were
performed to minimize the variability of HepG2 cell clumping
during the seeding process, rather than relying on a single
growth curve repeated in triplicate. Average 48-h titers for the
five recombinant viruses reinforced the results that S2 alone
can encode determinants of MHV host range. As shown in Fig.
2C, the average 48-h titer for V51 was 9.15  106 PFU/ml,
while those of the Full S, S2, and 3 region recombinants were
comparable at 5.19  106, 8.58  106, and 1.78  107 PFU/ml,
respectively. These average titers were all well over 400 times
those of the RBD and S1 recombinants (3.92  103 and 1.09 
104 PFU/ml, respectively), which were more comparable to the
A59 background level of 2  103 PFU/ml.
The novelty of host range determinants exclusively in S2
prompted a more detailed analysis of the substitutions in this
subunit. As previously discussed, four of the six S2 substitu-
tions reside in regions characterized experimentally, the PEP3
TABLE 2. Common substitution sites in S among MHV host
range models
Virus
S protein position by residue
936 939 949 1120
A59 M P S I
pi23a M P R I
pi600a L P R T
MHV/BHKa L P R T
V51 V L I T
C4b M P R T
a Reference 52.
b Unpublished data.
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putative fusion peptide (41) and HR1 (9, 16) (Fig. 1). Preserv-
ing the substitutions in PEP3 and HR1 as an intact unit in the
PEP3/HR1 recombinant provided a 48-h postinfection titer for
HepG2 cells of 1.79  106 PFU/ml (Fig. 3A). This titer was
about 10-fold lower than those of V51 and the S2 recombinant
(2.9  107 and 2.52  107 PFU/ml, respectively). The PEP3
and HR1 recombinants divide this four-substitution unit into
the separate functional regions. Forty-eight-hour titers for ei-
ther recombinant were about 2 logs or more lower than the
titers determined when the substitutions are preserved as a
unit, although the PEP3 recombinant was more robust at 5.3 
103 PFU/ml than was the HR1 recombinant at 10 PFU/ml. The
939L and 949I mutations in PEP3 and HR1 that are common
to other host range model systems mentioned previously (see
“Sequence analysis of host range mutants” above) were incor-
porated into the common sites recombinant. It replicated to
9.7  102 PFU/ml by 48 h postinfection, comparable to the A59
background level of 5.7  102 PFU/ml (Fig. 3A).
The potential contribution of the 1120T and 1179A substi-
tutions located in the linker region between HR1 and HR2
(Fig. 1) prompted the construction of three additional recom-
binants that paired the PEP3 or HR1 substitutions with 1120T
and 1179A (PEP3-linker recombinant and HR1-linker recom-
binant, respectively) or the 1120T and 1179A substitutions
alone (linker recombinant). By 48 h, the HR1-linker recombi-
nant titer was 7.7  102 PFU/ml, over 2 logs below the titer for
PEP3/HR1 at 4.43  105 PFU/ml (Fig. 3B). The PEP3-linker
recombinant titer of 3.3  105 PFU/ml was comparable to the
PEP3/HR1 recombinant titer of 4.43  105 PFU/ml. Replica-
tion of the linker recombinant at 48 h was virtually undetect-
able by plaque assay. While not as robust a phenotype as the S2
recombinant with all six substitutions (2.5  106 PFU/ml), it is
clear that coordinating mutations in PEP3, HR1, and the
FIG. 2. Mapping of host range determinants on human HepG2
cells. Monolayers of HepG2 cells were infected at an MOI of 5, and
virus titers at indicated time points were determined via plaque assay
with murine DBT cells. (A and B) Representative growth curves re-
ported as PFU per milliliter. Data points are identified by the key
provided on the far right. (C) Average titers of recombinants across
multiple growth curves. The black squares indicate the average titers,
while the arms signify the maximum and minimum titers recorded per
recombinant across a minimum of four growth curves.
FIG. 3. Mapping of host range determinants within the S2 subunit.
Monolayers of HepG2 cells were infected at an MOI of 5, and virus
titers at indicated time points were determined via plaque assay with
murine DBT cells. (A) Representative growth curve dissecting the
contributions of substitutions in the PEP3 and HR1 domains on host
range. (B) Titers for HepG2 cells at 48-h postinfection, focusing on S2
substitutions in combinations. Infections per recombinant were per-
formed in triplicate, with error bars (standard deviations) indicated.
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linker region are important mediators of V51 host range ex-
pansion.
We previously reported that V51 could also replicate in
Chinese hamster ovary (CHO) and human breast carcinoma
(MCF7) cells (3). To determine whether the S2 substitutions
important in HepG2 entry represent more generalized medi-
ators of entry into normally nonpermissive cell lines, 24- and
48-h titers were also measured for these cell lines. In CHO
cells, the S2 substitutions were also important host range me-
diators, as the 48-h peak titer for the S2 recombinant was
9.65  105 PFU/ml, comparable to the V51 titer of 2.7  106
PFU/ml (Fig. 4A). This result suggests that the S2 substitutions
are not specific for entry into HepG2 cells. When we subdi-
vided the S2 mutations, the PEP3/HR1 recombinant replicated
to 6.3  103 PFU/ml by 48 h postinfection, about 2 logs below
the value for the S2 recombinant, but 1,000-fold higher than
the values for HR1 and common sites recombinants or A59 (all
three of which were not detected via plaque assay at 48 h).
MCF7 cells are permissive to initial infection by V51 and the
S2 and PEP3/HR1 recombinants; however, the infection ap-
pears to stall and titers decline by 48 h (Fig. 4B).
Immunofluorescence analysis of infected cells. Despite the
evidence that MHV infection is regulated at the level of re-
ceptor binding and entry, we were concerned about a possible
block at a postentry stage that did not allow for the recovery of
some recombinants from cells (i.e., assembled virus was re-
tained in the cells). To verify that recombinants incapable of
productively replicating in HepG2 cells were blocked at cellu-
lar entry, monolayers infected with a subset of the recombinant
virus panel were immunolabeled with an anti-nucleocapsid
protein monoclonal antibody. Reflecting the growth curve
data, the Full S, S2, 3 region, and PEP3/HR1 recombinants all
displayed qualitatively strong but varying degrees of nucleo-
capsid staining similar to that with V51 (Fig. 5). This result was
in marked contrast to the result for recombinants unable to
replicate above A59 background levels in HepG2 cells as as-
sessed by plaque assay. By immunofluorescence, only a rare
stained cell could be located in the monolayers for the RBD,
FIG. 4. Recombinant virus replication in CHO and MCF7 cells.
Monolayers of cells were infected at an MOI of 5 in triplicate, and
titers at 24 and 48 h were determined by plaque assay with DBT cells.
Infections per recombinant were performed in triplicate, with error
bars (standard deviations) indicated. The bar labels at the bottom
apply to both panels. (A) Hamster CHO cells. (B) Human MCF7 cells.
FIG. 5. Immunofluorescence analysis of HepG2 cells. Monolayers of HepG2 cells infected at an MOI of 5 were fixed and stained with anti-N
protein monoclonal antibody. Photos are representative fields for each recombinant.
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S1, PEP3, HR1, and common sites recombinants, a pattern
seen with A59 as well. The staining pattern mirrors the plaque
assay data in other cell types, such as CHO cells, again sug-
gesting that a block at entry is responsible for the lack of
recovery of some recombinant viruses (data not shown).
Receptor usage. We previously reported that V51 had
broadened its receptor affinity such that it could utilize human
CEACAMs to initiate infection (3). Given that changes facil-
itating host range expansion were mapped to the S2 subunit
and not the RBD or S1, we explored the recognition of the
high-affinity MHV receptor CEACAM1a with select members
of our recombinant panel. ST cells are normally nonpermissive
to MHV infection by either A59 or V51 (titers at time zero
were approximately 2  104 to 4  104 PFU/ml, decreasing at
30 h postinfection to 1  102 or 7.4  102 PFU/ml, respec-
tively) (3, 4). A similar nonpermissive phenotype was seen
following V8, V19, and V30 virus infection as well (data not
shown). To overcome this barrier, ST cells were modified to
stably express the murine CEACAM1a receptor from a plas-
mid (ST-CEACAM1a) (29). ST-CEACAM1a cells were inoc-
ulated with V51, and select recombinants were then used to
analyze receptor usage. V51 and the Full S and S2 recombi-
nants (2.2  104, 9.8  102, and 7.1  103 PFU/ml, respec-
tively) replicated to titers 150-fold below those of A59 and the
S1 recombinant (8.1  106 and 3.7  106 PFU/ml, respectively)
(Fig. 6A). Both V51 and the S1 recombinant share the seven
substitutions in the S1 subunit, but these changes do not permit
robust ST-CEACAM1a-mediated infection in the context of
V51 or the Full S recombinant. S1 recombinant replication is
comparable to that for A59, suggesting that substitutions in S1
do not radically affect the ability of the V51 RBD to recognize
CEACAM1a. Interestingly, the S2 recombinant titers lagged
behind those of A59, despite possessing S1 from A59. Viral
replication titers qualitatively correlated with results of anti-
nucleocapsid protein immunofluorescence analysis of infected
ST-CEACAM1a cells, where nucleocapsid-positive cells were
readily detected with A59 and the S1 recombinant, but not with
V51 or the Full S and S2 recombinants (data not shown).
The monoclonal antibody CC1 likely prevents A59 infection
by specifically binding to a location on CEACAM1a that over-
laps with the A59 binding site, thus blocking viral access to the
receptor (22, 55). Pretreatment of ST-CEACAM1a cells with
CC1 effectively inhibits infection by A59 and the S1 recombi-
nant, dropping 24-h titers 100,000-fold or more (Fig. 6A). The
effect of CC1 on the limited replication of V51 and the full S
and S2 recombinants was minor, about 70-fold at maximum for
V51. Isotype-matched control antibodies did not specifically
reduce titers (data not shown). On DBT cells, CC1 blockade of
CEACAM1a again reduces A59 and S1 recombinant titers by
50,000- and 5,000-fold, respectively (Fig. 6B). V51 and the S2
and Full S recombinants are more resistant to CC1 blockade,
dropping titers only 20-fold at maximum for the Full S recom-
binant and much less for V51 and S2 recombinant. Taken
together, the receptor blockade data suggest either that V51
and the S2-based recombinants recognize alternate receptors
on permissive cells (DBT cells) or that the mutated S2 fusion
domain allows for CEACAM1a-independent entry in multiple
cell types (HepG2, MCF7, and CHO cells).
Previous studies have demonstrated that tissue culture ad-
aptation of viruses may result in the use of the ubiquitous
proteoglycan heparan sulfate (HS) as a receptor or coreceptor,
as demonstrated with Sindbis virus and the MHV/BHK variant
(17, 31, 50). The mutations in V51 do not generate any HS
binding sites (characterized by an XBBXBX motif) readily
identifiable in the primary structure of the protein. The N434K
FIG. 6. Receptor utilization by recombinant viruses. Monolayers of
ST-CEACAM1a, DBT, K1, or pgsA-745 cells were infected at an MOI
of 5, and at 24 h postinfection, titers were determined via plaque assay
on DBT cells. Infections were performed in triplicate, with error bars
(standard deviations) indicated. (A) ST-CEACAM1a cells were un-
treated or pretreated with blocking antibody CC1. (B) DBT cells were
untreated or pretreated with CC1. (C) HS-expressing CHO cells or
nonexpressing pgsA-745 cells were infected with A59 or V51.
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substitution is the only gain of a basic residue present, but the
context of this change does not appear to form an HS consen-
sus motif. To eliminate HS as a potential receptor for V51,
CHO K1 cells expressing HS and pgsA-745 cells, CHO deriv-
atives incapable of producing HS, were evaluated for V51
infection. At 48 h postinfection, titers averaged 1.9  105 and
2.3  105 PFU/ml on K1 and pgsA-745 cells, respectively (P 
0.27), suggesting a lack of HS involvement (Fig. 6C). A59 was
unable to generate appreciable titers in either of these cell
lines.
With the dramatic impact of the S2 substitutions, we were
intrigued by the idea that S2 substitutions may facilitate recep-
tor binding directly, thereby alleviating the need for the tradi-
tional RBD and CEACAM1a receptors for docking and entry.
We designed a construct that deleted residues 21 to 560 of S1,
while preserving the amino-terminal signal sequence, but were
unable to recover virus with this deletion. S1 deletions are
tolerated, particularly in JHM-derived strains, suggesting ei-
ther that the deletion was too large to recover a functional S or
that the RBD is still required for the entry of V51 (25).
DISCUSSION
The current working model for MHV entry into cells begins
with the S1 subunit binding to a receptor, thereby inducing a
conformational change in S2 that drives cell membrane-virion
fusion (26). This model is analogous to that for other viruses
possessing a class I fusion protein, such as HIV and influenza
(23). Although a complete crystal structure for MHV spike is
sorely missing, the structures for several distinct domains, in-
cluding those of HR1 and HR2 in a presumed postfusion
canonical six-helix bundle, have been solved (68). The mechan-
ics of the trigger that drives the reorganization of S2 into this
fusion core structure have yet to be determined, but experi-
mental evidence points to regions in S1 interacting with S2 to
drive this process.
Previously, mutations in the RBD and S1 have been identi-
fied as mediating host range expansion. Host range variant
MHV/BHK was reportedly able to initiate low levels of entry
into cell lines from several species, with the phenotype mapped
to 21 substitutions and a unique 7-amino-acid insert in S1
despite the presence of 57 total substitutions in S (52, 53, 60).
This mapping was limited to binding studies and replication in
hamster cells, as the identified changes did not allow for prog-
eny virion recovery or subsequent rounds of infection in non-
murine cells. The inability to produce secondary rounds of
infection strongly suggests that an unknown number or com-
bination of the remaining 36 amino acid changes scattered
throughout S are vital to its extended host range phenotype. It
was demonstrated more recently that during propagation,
MHV/BHK acquired two new HS binding sites (one in S1 and
the other in S2) and preserved a third at the S1-S2 cleavage site
due to the apparent noncleavage of the S protein of this mu-
tant (17). The presence of these sites, particularly the two
newly acquired sites, bestowed upon MHV/BHK the ability to
use HS as a receptor for entry into HeLa cells (18). The
functionality of HS as a receptor in cells from additional spe-
cies has not been reported, so it is unclear whether this is a
HeLa cell-specific phenomenon or more broadly applicable to
host range expansion.
Early studies in our laboratory showed that V51 infected
BHK cells expressing high levels of human CEACAMs 1 and 5
(identified as BGP and CEA, respectively, under the previous
nomenclature system) with low levels of efficiency, noting that
many CEACAM 1- and 5-expressing cells were not produc-
tively infected. We concluded either that multiple combina-
tions of CEACAM receptors functioned in docking and entry
or that other mechanisms may help promote entry into human
cells (3). In contrast to results for MHV/BHK and this earlier
work, determinants of host range for V51 mapped exclusively
to the S2 subunit, a phenomenon not previously documented
for any CoV. The S2 changes also appear to represent a gen-
eralized alteration, facilitating entry into not only human cell
lines but also those of hamster and monkey origin (data not
shown). While the six substitutions in S2 were sufficient to
mediate extended host range, the contribution of substitutions
in S1 or elsewhere in the genome is also likely to be important
for maintenance of the expansion, perhaps promoting higher-
affinity interactions between the virus and cell surface to pro-
mote S2-driven entry. We have yet to examine potential ge-
netic changes outside S, such as in the replicase genes or other
structural proteins, that may be involved in V51 host range
expansion. Experimental evidence from SARS-CoV suggests
that alterations in its RBD were responsible for the initial host
range jump; however, positive selection for mutations within
the heptad repeats of S2 may have occurred once the virus
entered the human population to refine the SARS-CoV inter-
action with the angiotensin-converting enzyme 2 receptor (24,
38, 75).
S2 has not been shown to possess inherent receptor binding
activity (58), an observation supported by our lack of recovery
of a recombinant that attempted to delete the RBD and addi-
tional S1 residues, although such a large deletion may sterically
destroy the functionality of the remaining S glycoprotein. How-
ever, numerous studies have documented how substitutions in
S2 alter properties of S1 and S as a whole, including stabilizing
the S1-S2 association, altering fusion behavior, and changing
tissue tropism (7, 18, 25, 27, 40, 43, 49, 51). Clearly, substitu-
tions in S2, either alone or paired with corresponding sub-
stitutions in other regions of S, can have profound impacts
upon the behavior of S, even leading to changes in host range.
The coordination of S1 and S2 substitutions and their influence
on host range was demonstrated recently with MHV/BHK
entry into HeLa cells (18) and in our coinfection model (data
not shown).
Most intriguing is the location of the identified substitutions
in and adjacent to HR1, a conserved hallmark feature of class
I viral fusion proteins. As previously mentioned, heptad repeat
domains pack together to form the characteristic six-helix bun-
dle believed to drive viral entry (14, 23). The M936V and
P939L substitutions are both located adjacent to HR1 in PEP3,
a region identified based on its hydrophobic composition as a
potential fusion peptide (12, 41). The F948L and S949I sub-
stitutions are located at the amino-terminal end of HR1, as
defined by Bosch et al., beginning with residue 947 (9).
The four clustered PEP3-HR1 substitutions all result in in-
creasingly hydrophobic residues, an interesting feature relative
to their locations in domains defined by such traits. The inclu-
sion of these substitutions is not computationally predicted to
extend the recognized helix of HR1 using the LearnCoil-VMF
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program, an identifier of coiled-coil regions in viral fusion
proteins (54). The presence of the four clustered substitutions
at the amino terminus of HR1 is also interesting, as this area is
not required for the formation of stable HR1-HR2 interac-
tions, a key step in six-helix bundle construction in earlier
studies (9, 68). Purified HR1 peptides used in one earlier study
did not include the 948 and 949 residues of interest in V51;
rather, they began at residue 953 and yet still complexed with
HR2 (9). Additionally, a portion of the amino-terminal end of
this HR1 peptide was susceptible to proteinase K degradation
even when complexed with HR2, further suggesting a lack of
involvement in interactions with HR2 in this system. A recent
crystal structure of the MHV six-helix bundle further clarifies
that the extreme amino-terminal end of HR1 is not involved
directly in the fusion core complex, as the interaction with HR2
is more central (68). Similar crystal structures are available for
SARS-CoV and human CoV NL63 (57, 69, 76). While these
models do not demonstrate involvement of the equivalent 948
and 949 residues for other CoVs in six-helix bundle formation,
these positions may be influencing HR interactions in the con-
text of virus. The coiled-coil structure, upon fusion, likely
brings the amino-terminal end of HR1 and the PEP3 region in
closer proximity to the transmembrane region, possibly provid-
ing an opportunity for the involvement of the PEP3-HR1 clus-
ter of substitutions in facilitating or stabilizing the fusion core
complex. Also revealed by the MHV crystal structure is that
the linker region can be radically modified and still permit HR1-
HR2 fusion core formation. This revelation complicates the in-
terpretation of the influence of the 1120T and 1179A substitu-
tions, as they appear to contribute to the host range phenotype as
evidenced by the subtle difference in phenotype recovery be-
tween the S2 and PEP3/HR1 recombinants. Alternatively, the
HR1 and PEP3 substitutions may not be involved in the for-
mation of the six-helix bundle but are important in coordinat-
ing S1-S2 interactions and the fusion trigger. S structural data
for the pre- and postfusion states are desperately needed to
resolve this issue.
Of great interest is the location of the PEP3-HR1 substitu-
tions when viewed in light of growing optimism for HR-based
peptide inhibitors of viral fusion. The recent approval of the
HR2-based HIV fusion inhibitor enfuvirtide (T20 or Fuzeon)
for HIV treatment is just one example, but many others have
been evaluated in vitro, including for SARS-CoV (8, 35, 39, 48,
63, 73). Another host range model system using the retrovirus
avian sarcoma and leukosis virus subgroup A (ASLV A) pas-
saged virus in the presence of a HR2-based inhibitor (1). Such
passage readily selected peptide-resistant variants, several with
substitutions in the amino-terminal portion of HR1. A subset
of these variants was able to infect nonavian cells, including
human cells, and displayed altered SU-TM (the S1-S2 equiv-
alents, respectively, in retroviruses) stability. In those host
range variants displaying the strongest replication in human
cells, the responsible substitutions were preliminarily mapped
to the interface between HR1 and HR2. Paralleling the MHV
model, additional ASLV host range mutants were generated
with the governing mutations mapping to SU (47). We are in
the process of evaluating the sensitivity of V51 to an HR2-
based peptide to understand whether the changes in HR1 of
V51 are altering the fusion process at the six-helix bundle level.
We presume that increased resistance to the HR2 peptide
would indicate that the fusion core is affected, while no change
in resistance suggests that the substitutions are involved in
stabilizing S1-S2 or receptor interactions. The panel of viruses
produced in the study by de Haan et al. was reportedly inhib-
ited effectively with an HR2-based peptide (18), suggesting
that those HR1 substitutions were involved in processes other
than fusion core formation, perhaps associated with MHV/
BHK usage of HS as a receptor in HeLa cells.
The loss of affinity for CEACAM1a based on changes in S2
was particularly interesting, as the substitutions in the RBD
alone were not the predominant mediators of host range ex-
pansion. Recombinants harboring S1 from V51 could still ini-
tiate infection via CEACAM1a, as demonstrated by the S1
recombinant (Fig. 6A). The MHV/BHK variant displayed a
similar phenotype, as it was less sensitive to soluble receptor
neutralization but still capable of binding to CEACAM1a (53,
60). Particularly intriguing were the 3 region and S2 recom-
binants. Both recombinants possess at a minimum the A59
RBD, yet they recovered less than 1% of the A59 titers on
ST-CEACAM1a cells. While we do not know the CEACAM1a
binding affinities of our recombinant panel, it appears that the
substitutions outside the RBD modulate either CEACAM1a
binding or S1-S2 interactions and prevent the entry of these
recombinants and V51. In the context of the working MHV
entry model, the V51 S1 subunit is clearly able to transfer the
receptor binding signal to an A59-based S2, as demonstrated
by the robust replication of the S1 recombinant, but the inverse
situation is apparently not occurring normally, if at all. This
result may indicate that the V51 S2 substitutions are altering
S1-S2 or receptor interactions, the fusion trigger, and not
HR1-HR2 interactions.
The convergence of phenotype between V51- and HR2-
resistant ASLV isolates deserves attention. The common lo-
calization of mutations mediating host range to domains con-
served in class I fusion proteins suggests that such proteins may
have an inherent plasticity in the mechanism that could be
exposed under the correct environmental conditions, such as
fusion-specific inhibitory drugs. The selective pressure of the
immune system may be the power in the system limiting evo-
lution in the fusion mechanism at present. This power would
explain why changes thought to be responsible for SARS-CoV
emergence occurred in the RBD, although this result has yet to
be evaluated in the context of virus infection. There are addi-
tional changes in SARS-CoV S, relative to earlier animal iso-
lates, with unknown functions. Also, as Amberg et al. pointed
out, the ASLV host range isolates were more sensitive to
neutralizing antibodies and had a lower activation threshold
necessary to induce SU conformational changes (1). We do not
have enough data on S1-S2 stability or the sensitivity of V51 to
neutralizing antibodies at present to make relevant compari-
sons with ASLV. It will be interesting to follow the develop-
ment of the enfuvirtide story, as it brings together all the
variables discussed here: an immunosuppressed environment,
a class I fusion protein, and a fusion-inhibiting compound.
While clear host range variants have yet to be described, this
therapeutic intervention may allow evolution in the fusion
mechanism to manifest itself as altered HIV tropism and force
us to carefully evaluate HR2-based compounds as therapeutic
options.
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